Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March ...

Belghiti now expects that the biopharmaceutical company will post earnings of ($2.74) per share for the quarter, up from their previous forecast ... Shares of CRBP stock opened at $6.79 on Friday.

Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Outperform recommendation. Analyst Price Forecast Suggests 690. ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $7.87, with InvestingPro data showing the stock is currently trading below its Fair... In a recent ...

Investors in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 17, ...

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western studyFast Track Designation granted by FDA for CRB-701 to ...

Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the Earnings Calendar to see dates for upcoming earnings announcements.

Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.9% over the past four weeks, the stock looks well positioned for a trend ...

Oppenheimer analyst Jeff Jones reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...